IP Verse

Generics Uk competitive analysis

Explore patent oppositions filed by Generics Uk against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026

Patent Number	Title	Applicant	Opposition Date
EP4197530	Ribociclib Tablet	NOVARTIS	Aug 11, 2026
EP2396005	Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or Hyperglycemia	BOEHRINGER INGELHEIM	Jul 24, 2026
EP3834824	Method Of Treating Cancer Using Selective Estrogen Receptor Modulators	DUKE UNIVERSITY	Jul 21, 2026
EP4021507	Methods Of Treating Heart Failure With Reduced Ejection Fraction With Dapagliflozin	ASTRAZENECA	Jul 1, 2026
EP3823631	Methods Of Treating Hfpef Employing Dapagliflozin And Compositions Comprising The Same	ASTRAZENECA	May 20, 2026
EP4114391	Methods Of Treating Estrogen Receptor-Associated Diseases	OLEMA PHARMACEUTICALS	Apr 9, 2026
EP3411021	New Use Of A Combination Of Sacubitril And Valsartan	NOVARTIS	Feb 12, 2026
EP3826642	Empagliflozin For Use In Treating Alport Syndrome	BOEHRINGER INGELHEIM	Feb 6, 2026
EP3435996	Methods Of Treatment Of Cholestatic Diseases	GENFIT	Jan 30, 2026
EP4212152	Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure	NOVARTIS	Jan 28, 2026

Discover the latest PTAB cases involving Generics Uk, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Generics Uk with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
GENERICS UK	319	-	-	-
BOEHRINGER INGELHEIM	45	232	8	9
NOVARTIS	12	564	-	21
NOVO NORDISK	22	136	1	9